u/Peptide_Guide_

Somewhere around 35 or 40, even people who train hard and eat well hit a wall. Workouts feel flat, recovery drags, and fasting glucose creeps up with nothing changing on the diet side. One proposed piece of that puzzle is MOTS-C, a 16 amino acid peptide discovered in 2015 by a USC group. Your mitochondria make it, its levels rise with exercise, and circulating levels appear to fall with age. This is the full breakdown: how it works, what it does and doesn't do, the human data, side effects, dosing, stacking and reconstitution.

How MOTS-C works

Most peptides are encoded in nuclear DNA. MOTS-C is encoded in the mitochondrial genome, inside the 12S rRNA gene. It doesn't grab AMPK directly. It interferes with the folate cycle, which makes a molecule called AICAR accumulate, and AICAR flips the AMPK switch. AMPK is the cell's fuel gauge, and activating it pushes cells to take up glucose and burn fat.

Under metabolic stress, cell and mouse work shows MOTS-C moving from the mitochondria into the nucleus. There it binds DNA and regulates gene expression, including antioxidant response genes. A peptide born in one genome changing what another genome reads is why people call it dual-genome crosstalk. This is why the community frames it as the software upgrade, while SS-31 is the hardware, working on the physical membrane.

Exercise mimetic, with a catch

Reynolds 2021 (Nature Communications) found that MOTS-C levels rise in human muscle and plasma after exercise, and that treating mice of different ages improved their physical performance. That's where the "exercise mimetic" label comes from.

Here's the catch. I couldn't find a completed human trial of injected MOTS-C for any metabolic or performance use. The human evidence is observational: the body makes more of it when you exercise. Whether an injection reproduces that in people hasn't been tested.

What it does and doesn't do

MOTS-C isn't a fat burner and it doesn't suppress appetite the way GLP-1s do. Any weight change is an indirect effect of how cells handle fuel. Three downstream mechanisms get cited: browning of white fat into calorie-burning beige fat, mitochondrial biogenesis through PGC-1α, and lower myostatin expression, which would protect muscle. All three come mostly from mouse and cell work, and they're thinner than the AMPK evidence.

The mouse data also has a limit. The metabolic benefits show up in animals under stress, like high-fat diets or ovariectomy, with no apparent effect in unchallenged rodents. One line of work saw benefit in male mice but not pre-menopausal females. If you're lean, insulin-sensitive and 25, the mouse data doesn't promise you much.

The liver data

The human liver numbers come from CB4211, a MOTS-C analog, not MOTS-C itself. In a Phase 1b study (CohBar, company-reported), 20 obese adults with fatty liver got 25 mg subcutaneously every day for 4 weeks. ALT fell 21% versus a 4% rise on placebo. AST fell 28% versus an 11% drop on placebo. Liver fat on MRI fell about 5 percentage points in both groups, so the drug didn't separate from placebo there.

So enzymes moved and fat didn't. It's also 20 people, 4 weeks, and a dose roughly 10 to 25 times what the community uses. It's not a fatty liver treatment, and it isn't an answer to what injected MOTS-C does at 1-2 mg.

Side effects and who should skip it

There's no peer-reviewed human safety data for injected MOTS-C. Community reports put severe reactions around 10% of users, including systemic hives, sudden hypoglycemia, palpitations and heart rate spikes. That number comes from user reports, not a trial.

Hypoglycemia is most likely during hard resistance training or when MOTS-C is stacked with metformin, berberine, GLP-1s or insulin. Carry fast carbs.

For injection site reactions or hives, the community workaround is switching from SubQ to IM in the deltoid or glute. The reasoning is that muscle has fewer mast cells than fat. It's plausible, and it's anecdotal.

Skip it entirely if you have a history of severe allergic reactions or MCAS, are a drug-tested athlete (WADA lists it as an AMPK activator), are pregnant or breastfeeding, or have an unmanaged cardiac condition.

Dosing tiers (community-reported)

None of these come from human trials of injected MOTS-C. Tier 1 is a screening dose of 250-500 mcg/day for 2 weeks, SubQ or IM, just to see how you react. Tier 2 is 1-2 mg/day, 5 days on and 2 off, for 8 weeks, which is the usual range for metabolic and exercise goals. Tier 3 is a 2-5 mg/day ceiling on the same 5/2 schedule for 8-12 weeks, for significant insulin resistance or inflammation under close tracking.

The usual cycle is 8 weeks on, 8 weeks off. That's convention, not data. Start low, even if you think you're not the allergic type.

Sequencing with SS-31

The community theory is to fix the base before you build on it. SS-31 binds cardiolipin in the inner mitochondrial membrane and stabilizes it. MOTS-C expands capacity and reprograms fuel use. The reasoning goes that ramping up production on damaged membranes is backwards.

The popular protocol runs SS-31 alone at 1-5 mg/day for weeks 1-4. Then MOTS-C at 1-2 mg/day joins for weeks 5-12, with SS-31 overlapping for 4-8 weeks before tapering. Some people add Humanin as a third phase for neuroprotection and vascular health.

No study tests any of this combination, and SS-31's own human record is mixed. It's approved only for Barth syndrome and missed its endpoints in several larger trials. Treat the sequence as a reasoned hypothesis.

Reconstitution and stability

Add 2 mL of bacteriostatic water to a 10 mg vial and you get 5 mg/mL. A 1 mg dose is 0.2 mL, which is 20 units on a U-100 insulin syringe.

You'll hear that MOTS-C degrades within 15 minutes of reconstitution. That mixes up two things: how fast it clears from your blood and how long it lasts in a vial. A short plasma half-life says nothing about shelf stability. It also doesn't rule out lasting effects, since a peptide that changes gene expression can outlast its time in circulation.

Vendors and users report 30 days of stability refrigerated. I haven't seen a peer-reviewed stability study, so treat that as a working number.

Where it stands legally

MOTS-C isn't approved for human use. FDA staff recommended against adding it to the 503A bulk substances list, and the advisory committee voted 7-5-2 in favor anyway. Rulemaking typically takes 8-18 months, so the status can still change.

What MOTS-C can't do for you

It amplifies habits you already have. It can't replace progressive resistance training, protein, sleep or baseline hormones, and it won't fix a broken foundation. If you use it, start with a screening dose, go slow and cycle it.

TL;DR

• MOTS-C is a mitochondrial-encoded peptide that activates AMPK by raising AICAR and, under stress, moves to the nucleus to regulate genes, mostly shown in cell and mouse work.
• Its levels rise after exercise in humans, but I couldn't find a completed human trial showing that injecting it does the same.
• The fat browning, PGC-1α and myostatin mechanisms are mostly mouse and cell data, and mouse benefits appear mainly in metabolically challenged animals.
• The 21-28% ALT/AST drop comes from CB4211, a MOTS-C analog, in 20 people at 25 mg for 4 weeks, and liver fat on MRI didn't separate from placebo.
• Dosing tiers, the roughly 10% severe reaction figure, the 30-day stability claim and the SS-31 sequence are all community-reported, not trial-derived.
• Start with 250-500 mcg, carry fast carbs around training and glucose-lowering drugs, and skip it if you have MCAS or allergy history, are pregnant or breastfeeding, or are drug-tested.

Check out the pinned Peptide Cheat Sheet for more. 

Not medical advice. Educational only.

Eloralintide is the amylin compound getting the most attention right now, and the data has moved quickly. Eli Lilly is developing it (LY3841136) as a long-acting, selective amylin receptor agonist for obesity, dosed once weekly. It works through amylin signaling and skips GLP-1 and GIP receptors entirely, which is why it keeps coming up.

What amylin does

Amylin is a hormone released alongside insulin after you eat. It slows gastric emptying, blunts glucagon, and promotes satiety. Eloralintide is built to hit that pathway for a long time. Its half-life in the single-dose study was about 13 to 15 days.

Phase 1

The 12-week multiple-dose study in adults with overweight or obesity found dose-dependent weight loss. Average reduction at week 12 ran from 2.6% to 11.3% across dose groups. The most common adverse events were decreased appetite, headache, and fatigue, mostly mild. Twelve weeks is too short to say anything about long-term results, but it was enough of a signal to keep going.

Phase 2

The 48-week Phase 2 trial in adults without type 2 diabetes reported weight loss of up to 20.1% at the top dose. That's the number that pushed Lilly into Phase 3. The Phase 3 program, called ENLIGHTEN, includes obesity as well as sleep apnea and knee osteoarthritis pain.

The tirzepatide combination

On September 30, Lilly reported 48-week Phase 2b results for eloralintide plus tirzepatide, which they call EloraTZP. It enrolled 367 adults with obesity or overweight and type 2 diabetes. The top combination, eloralintide 9 mg plus tirzepatide 15 mg, averaged 23.3% weight loss and a 2.9% drop in A1C. Tirzepatide 15 mg alone averaged 14.8% and 2.4%. Eloralintide alone ranged from 8.2% to 12.3%.

There's a cost. Across the combination arms, 10.8% to 27% of participants stopped treatment over adverse events, compared with 2.9% on tirzepatide alone. In the trial, the two drugs were separate injections, and Lilly plans Phase 3 with a co-formulation and a gentler escalation schedule.

I'd be careful about comparing that 23.3% to retatrutide. Different populations, different durations, and no head-to-head trial exists.

Why it's worth watching

Amylin gives researchers a way to work on appetite without leaning on the GLP-1 receptor. The question now is how much it adds on top of incretins and what the tolerability looks like once the dose goes up.

Eloralintide is investigational and not approved anywhere.

TL;DR

• Eloralintide is a once-weekly, selective amylin receptor agonist from Eli Lilly with a half-life of roughly two weeks.
• Phase 1 showed 2.6% to 11.3% weight loss at 12 weeks, and Phase 2 showed up to 20.1% at 48 weeks.
• It's in Phase 3 (ENLIGHTEN), including sleep apnea and knee osteoarthritis trials.
• EloraTZP, eloralintide plus tirzepatide, hit 23.3% weight loss at 48 weeks versus 14.8% for tirzepatide alone, with more treatment discontinuations.
• It's investigational, so everything here is trial data and nothing is established practice.

Check out the pinned Peptide Cheat Sheet for dosing info and more. 

Not medical advice. Educational only.

Visceral fat gets talked about mostly in terms of the waistline, but the fat itself sits wrapped around the liver, pancreas, and intestines, and what happens when it shrinks reaches a lot further than appearance.

The liver gets healthier

When visceral fat builds up, the liver often ends up storing excess fat too. Reducing visceral fat tends to pull liver fat down alongside it, improve insulin sensitivity, and ease the metabolic load the liver's carrying. Tesamorelin has some of the best data here. The original 412-patient trial (Falutz et al., NEJM 2007) found a 15.2% reduction in visceral fat over 26 weeks. A separate 12-month trial in patients with HIV-associated fatty liver disease (Stanley et al., Lancet HIV 2019, 61 participants) found tesamorelin reduced liver fat by 4.1 percentage points more than placebo, a 37% relative reduction.

The pancreas doesn't have to work as hard

Excess visceral fat drives insulin resistance, which forces the pancreas to pump out more insulin just to keep blood sugar controlled. As visceral fat drops, insulin sensitivity tends to improve, so the pancreas needs to produce less insulin to do the same job. That's part of why losing visceral fat specifically can improve metabolic health meaningfully before someone looks noticeably leaner. GLP-based therapies work on this from multiple angles at once: less food intake, less overall body fat, less visceral fat specifically, and better glucose control on top of that.

Heart-related markers move too

Visceral fat is tied to high triglycerides, poor cholesterol ratios, higher blood pressure, and chronic low-grade inflammation. In that same original tesamorelin trial, the 15.2% visceral fat reduction came with a roughly 50 mg/dL drop in triglycerides and an improved total cholesterol to HDL ratio. GLP-1 therapies show a similar pattern. A 2023 meta-analysis pooling 30 randomized trials and 1,736 people (Liao et al., PLOS One) found GLP-1 receptor agonists significantly reduced both visceral adipose tissue and liver fat content across the pooled data.

Inflammation drops along with it

Visceral fat isn't inert. It contains immune cells and actively releases inflammatory signaling molecules into the bloodstream. The more dysfunctional it becomes, the more it contributes to chronic low-grade inflammation, which is linked to cardiovascular disease, insulin resistance, fatty liver, and type 2 diabetes. Bringing visceral fat down shifts the body toward a less inflammatory state, and that shift can start showing up in bloodwork before it's visible anywhere else.

Where the strongest evidence actually sits

Worth being specific about the two approaches here instead of treating them as interchangeable. Tesamorelin's strongest data isn't about general weight loss, it's specifically about visceral fat. In the original 412-patient trial, visceral fat dropped 15.2% while subcutaneous fat barely moved, and that population was people with HIV-associated abdominal fat accumulation, which is tesamorelin's actual studied use case. GLP-1 therapies work through a different route, appetite and broader fat loss, but multiple meta-analyses, including the 1,736-person pooled analysis above, confirm they reduce visceral and liver fat specifically too, not just total body weight.

Bottom line

Losing visceral fat changes the environment your organs are actually operating in. The liver carries less ectopic fat and metabolic stress. The pancreas needs less insulin to keep glucose controlled. The cardiovascular system runs in a better lipid, blood pressure, and inflammatory environment. And the whole body ends up carrying a lower metabolic burden than the scale alone would suggest.

TL;DR

• Visceral fat surrounds the liver, pancreas, and intestines, and reducing it improves far more than waist size, including liver health, blood sugar control, cholesterol, blood pressure, and inflammation.
• Tesamorelin's original 412-patient trial found a 15.2% visceral fat reduction over 26 weeks, and a separate 12-month trial found a 37% relative reduction in liver fat in HIV patients with fatty liver disease.
• Reducing visceral fat eases pressure on the pancreas by improving insulin sensitivity, meaning less insulin is needed to control blood sugar.
• The same 412-patient tesamorelin trial found a roughly 50 mg/dL drop in triglycerides alongside the visceral fat reduction, and a 2023 meta-analysis of 30 trials and 1,736 people found GLP-1 therapies reduce both visceral and liver fat.
• Visceral fat actively releases inflammatory signals into the bloodstream, so reducing it shifts the body toward a less inflammatory state.
• Tesamorelin's strongest evidence is specifically for visceral fat reduction in the HIV-lipodystrophy population it was studied in, while GLP-1 therapies reduce visceral fat through a broader fat-loss mechanism, and both are backed by real trial data, not just theory.

Check out the pinned Peptide Cheat Sheet for dosing info and more. 

Not medical advice. Educational only.

Everything relevant gets sorted into five tiers, S down to D, based on real-world observed effectiveness across a wide range of goals.

One thing worth saying upfront: these rankings come from pattern observation across a lot of users, not controlled data, and individual response varies a lot. Someone can respond terribly to an S-tier compound and get incredible results from something sitting in C. Don't use this as gospel.

S-Tier: The Very Best

Retatrutide, BPC-157, GHK-Cu, HGH, MOTS-C, Tesamorelin, HMG, Selank, Epitalon, NAD+.

These are the compounds that consistently deliver the most dramatic, life-changing results across the widest range of people. If you're only going to research a handful of things in this space, this is the list to start with.

A-Tier: Very Good, Wide Application

TB-500, KPV, SLU-PP-332, Tirzepatide, CJC-1295, Semax, PT-141, Pinealon, HCG, SS-31, Melanotan 2, Ipamorelin

These are genuinely effective, just not quite S-tier. Some are highly user-dependent in how well they work. Some sit slightly below their S-tier counterparts in overall impact. And some, like SLU-PP-332, just haven't had their ideal human dosing figured out yet since the data is still almost entirely preclinical.

B-Tier: Decent, Effective When Used Correctly

AOD-9604, DSIP, Thymosin Alpha-1, IGF-1 DES/LR3, 5-Amino-1MQ, LL-37, Cagrilintide

These deliver real results, sometimes impressive ones, but the effectiveness swings a lot depending on how they're administered, and in several cases there are simply better alternatives available in a higher tier for the same goal.

C-Tier: Works, but Outclassed

Semaglutide, Sermorelin, Kisspeptin-10, ARA-290.

These compounds work. The issue is either heavy dose dependence or getting outperformed by something else on this list targeting the same goal. Semaglutide is the clearest example. It's effective, it's just been surpassed by tirzepatide and retatrutide for most people chasing the same outcome.

D-Tier: Skip These

Hexarelin, GHRP-2, GHRP-6, PEG-MGF, Follistatin-344, ACE-031.

The three GH secretagogues in this group work, technically, but their effects run inconsistent and fall well short of what you get from ipamorelin, tesamorelin, or CJC-1295. Not worth the research budget when better options exist in the same category.

Where do you disagree with this list? Curious what's landed differently for people running these in the real world.

Check out the pinned Peptide Cheat Sheet for dosing info and more.

Not medical advice. Educational only.

Retatrutide gets most of the oxygen in GLP-1 conversations right now, and it's not hard to see why - the phase 2 weight loss numbers were genuinely staggering. But a lot of that talk implies that tirzepatide is somehow a stepping stone you graduate past, which isn't really the right frame. Tirzepatide is still one of the most effective metabolic compounds ever put through a clinical trial. The question isn't whether retatrutide is more powerful. It might be. The question is whether that extra power actually matters for your specific situation.

What tirzepatide does

Tirzepatide hits two receptors: GLP-1 and GIP. GLP-1 drives appetite reduction, slows gastric emptying, and improves glycemic control. GIP adds insulin sensitivity and a fat-storage regulatory effect that works synergistically with GLP-1 rather than just duplicating it. The combined activation is what made tirzepatide's trial results unusual relative to everything that came before it.

In SURMOUNT-1 (Jastreboff et al., NEJM, 2022, n=2,539), participants on 15mg lost an average of 22.5% of body weight over 72 weeks. The 10mg arm averaged 21.4%. Those are large numbers for a dual agonist - not far off what retatrutide's Phase 2 data showed, and in a much larger, longer-established trial program.

Retatrutide adds glucagon receptor agonism to that mix, which is its primary differentiator. Glucagon drives hepatic glucose production, fat oxidation, and increased resting energy expenditure. That's the mechanism behind the larger weight loss ceiling. But it's also the mechanism behind most of what makes the safety profile less settled.

The evidence base is not a minor thing

Tirzepatide has FDA approval for type 2 diabetes (Mounjaro, 2022) and for obesity (Zepbound, 2023). It has years of real-world use behind it, Phase 3 data across multiple populations, and extensive safety and tolerability tracking across tens of thousands of patients. We actually know what it does to people over time in a way we simply don't for retatrutide yet.

Retatrutide doesn't have FDA approval as of now. Eli Lilly is planning to submit a Biologics License Application in Q1 2027, which puts realistic approval somewhere in late 2027 or early 2028 if everything goes smoothly. That's not close. Phase 3 data has been coming in - TRIUMPH-3 in July 2026 showed 22.6% average weight loss at 12mg over 80 weeks in patients with obesity AND established cardiovascular disease, which is genuinely significant. But a completed Phase 3 trial is still not an approved drug with years of post-market safety data.

If the question is purely "which one has more evidence behind it right now," tirzepatide wins without a contest.

The heart rate difference is worth understanding

One of the clearest practical differences between these two is cardiovascular. Retatrutide causes a dose-dependent increase in resting heart rate. Phase 2 data (Jastreboff et al., NEJM, 2023) showed the peak increase at 12mg was approximately 6.7 bpm, occurring around week 24 before declining toward baseline by weeks 36-48. The slide floating around citing 7-10 bpm overstates it slightly. Tirzepatide, by comparison, produces an increase closer to 1-4 bpm in trials.

The mechanism for retatrutide's larger effect is almost certainly glucagon. Glucagon receptor agonism raises resting metabolic rate, and one of the byproducts is chronotropic stimulation. This isn't necessarily a deal-breaker for most people, but for someone with preexisting tachycardia, an arrhythmia history, or just a general preference for not running their heart rate artificially higher, tirzepatide's profile is meaningfully cleaner on this specific variable.

Receptor bias and who actually responds

Retatrutide's glucagon component is heavier relative to its GLP-1/GIP activity than tirzepatide's profile. That matters for appetite. GLP-1 and GIP both have direct CNS effects on satiety signaling. Glucagon's appetite suppression is more indirect - it works partly through energy expenditure and partly through hepatic signaling rather than direct satiety receptor activation in the hypothalamus.

The result is something the community has been noting anecdotally for a while: some people on retatrutide don't get the same hard appetite suppression they'd expect from a drug producing 24% weight loss, and then switch to tirzepatide and find the appetite blunting significantly stronger for them. Both are real observations. Which one applies to you depends on your individual receptor sensitivity, which isn't knowable in advance.

The cardiometabolic picture

The broader health data for tirzepatide is extensive. Large human trials have documented improvements in triglycerides, LDL and non-HDL cholesterol, blood pressure, insulin sensitivity, fasting glucose, visceral fat, liver fat (MASH/NAFLD data specifically), inflammatory markers, and sleep apnea. This isn't speculative - it's documented across multiple Phase 3 programs in different populations.

Retatrutide's TRIUMPH-3 data showed similar improvements in triglycerides, non-HDL cholesterol, and systolic blood pressure in the cardiovascular disease cohort, which is encouraging. But the tirzepatide dataset is simply much larger and covers a longer time horizon.

The honest read

Retatrutide is likely to become the dominant pharmacological tool for severe obesity once it's approved and has safety data behind it. The triple agonism mechanism is genuinely distinct and the weight loss ceiling is probably higher. That's probably a few years out from real clinical availability.

But "probably more effective for extreme weight loss cases" isn't the same as "superior in all circumstances." For someone who needs to lose 15-20% of bodyweight, tirzepatide delivered that in a trial with 2,500 people and years of follow-up. For someone where a modest heart rate increase is a real concern, tirzepatide is the cleaner option right now. And for someone who responds strongly to GLP-1/GIP satiety signaling, the dual agonist may do more appetite work than the triple.

The point isn't that tirzepatide is better. It's that the comparison is more situational than the hype cycle suggests.

TL;DR

• Tirzepatide is a GLP-1 + GIP dual agonist. In SURMOUNT-1 (n=2,539), the 15mg dose produced 22.5% average weight loss at 72 weeks, published in NEJM 2022.
• Retatrutide adds glucagon receptor agonism on top of GIP and GLP-1, which raises the weight loss ceiling but also changes the safety and side effect profile.
• Tirzepatide has FDA approval for both type 2 diabetes (2022) and obesity (2023) and years of real-world data. Retatrutide's BLA isn't being filed until Q1 2027.
• Retatrutide's resting heart rate increase peaks around 6.7 bpm at 12mg in Phase 2 data, compared to approximately 1-4 bpm for tirzepatide - the difference is driven by glucagon receptor chronotropic effects.
• Some people experience less appetite suppression on retatrutide than expected due to glucagon's more indirect satiety mechanism, and respond more strongly to tirzepatide's heavier GLP-1/GIP satiety signaling.
• Tirzepatide has large documented improvements in cholesterol, triglycerides, blood pressure, visceral fat, liver fat, and sleep apnea across multiple Phase 3 programs.
• The right choice between them is situational - retatrutide's ceiling is likely higher for extreme obesity, but tirzepatide is the better-evidenced option for most people today.

Check out the pinned Peptide Cheat Sheet for dosing info and more.

Not medical advice. Educational only.

Epitalon doesn't get talked about the same way as some of the flashier longevity compounds, but the research behind it is some of the most specific mechanistic data in the whole peptide space. The thing it's most associated with is telomeres, which sounds abstract until you understand what telomeres actually do.

Your cells have an aging clock

Inside almost every cell, chromosomes carry your DNA. At the ends of those chromosomes are protective caps called telomeres. Think of them like the plastic tips on shoelaces - they stop the DNA from fraying during cell division. Every time a somatic cell divides, those caps get a little shorter. Eventually they get so short the cell can't divide normally anymore. It enters a state called replicative senescence, also known as the Hayflick limit. That process, playing out across billions of cells, is a core driver of how we physically age.

The enzyme that's supposed to fix this - and why it mostly doesn't

Telomerase is the enzyme responsible for rebuilding telomere length. The problem is that most adult somatic cells barely express it. It's essentially switched off. Some cells need it (stem cells, immune cells), but the average mature cell in your body isn't rebuilding its telomeres after division.

This is where Epitalon gets interesting. It's a synthetic tetrapeptide - four amino acids, Ala-Glu-Asp-Gly - developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, starting in the 1970s from pineal gland research.

What the data actually shows

The foundational study is Khavinson et al. 2003, published in the Bulletin of Experimental Biology and Medicine. They treated human fetal fibroblasts with Epitalon and observed telomerase activation. Treated cells reached 44 population doublings compared to 31 in controls - a roughly 42% extension of replicative lifespan past the Hayflick limit. The cells didn't just slow their decline; they kept dividing beyond where they'd normally stop. That's a significant result, though it's an in vitro finding in fetal cells, and for years it came from one research group.

That changed in 2025. Al-Dulaimi, Thomas, Matta, and Roberts at Brunel University London (an independent group with no Khavinson affiliation) published a study in Biogerontology confirming telomere elongation in both normal epithelial cells and fibroblasts. One nuance worth knowing: in normal cells, the mechanism was telomerase upregulation, as expected. In cancer cell lines, it was ALT activity (Alternative Lengthening of Telomeres) - a different pathway entirely. The slide version of this story presents one clean mechanistic chain, but the actual biology is more context-dependent than that.

Beyond telomeres: the pineal angle

Epitalon wasn't designed in a vacuum. It's the synthetic version of epithalamin, a peptide extract from the pineal gland, which is your brain's primary melatonin production center. That origin matters because the research on Epitalon goes beyond telomeres.

A Khavinson group study (PubMed ID 17969590) found that pineal peptides including Epitalon restored nocturnal melatonin secretion in aged monkeys and elderly humans with pineal insufficiency. Melatonin production naturally drops with age and so does the amplitude of circadian rhythm. Epitalon appears to partially restore that. There's also evidence of downstream effects on antioxidant defenses and age-related hormonal regulation, though this data is mostly animal and observational.

Does it actually extend lifespan

In human cells (in vitro): the evidence for telomere elongation and extended replicative capacity is reasonably solid at this point, with independent replication now behind it.

In animals: multiple murine studies from Anisimov and colleagues showed median lifespan extension of 12-24% in mice and rats. A 2006 study in the Annals of the New York Academy of Sciences reported female rats lived 25% longer on average. These are animal studies - the translation to humans isn't guaranteed.

In humans: there's no randomized controlled trial showing Epitalon extends lifespan or reverses aging in people. Khavinson's group reported improved survival in elderly patients treated with epithalamin over 6-15 year observational follow-ups, but that's one group's observational data, not RCT evidence. The honest read is that the human longevity case is plausible given the mechanistic and animal data, but it's still speculative. Don't let anyone sell you certainty here that doesn't exist.

TL;DR

• Telomeres shorten with each cell division and when they get critically short, cells stop dividing normally - this is a core mechanism of aging at the cellular level.
• Epitalon is a synthetic tetrapeptide derived from pineal gland research, developed by Khavinson's group in Russia starting in the 1970s.
• Khavinson et al. 2003 showed Epitalon activated telomerase in human fetal fibroblasts and extended their replicative lifespan by roughly 42% past the Hayflick limit.
• A 2025 study from Brunel University independently confirmed telomere elongation in human cell lines, via telomerase upregulation in normal cells and ALT activity in cancer cells.
• Animal studies (Anisimov et al.) showed median lifespan extension of 12-24% in mice and rats across multiple studies.
• Epitalon also appears to restore nocturnal melatonin secretion in aged subjects in animal and observational human data, suggesting effects beyond telomeres alone.
• There's no RCT evidence for lifespan extension in humans - the animal and in vitro data is promising but the human longevity case is still speculative.

Check out the pinned Peptide Cheat Sheet for dosing info and more.

Not medical advice. Educational only.

CJC-1295 and tesamorelin get compared constantly because they're both GH secretagogues working through the same GHRH receptor, but they're built for different jobs entirely.

Same receptor, very different design

Both stimulate the body's own GH and IGF-1 output through the GHRH receptor. Where they split is duration and evidence base. CJC-1295 with DAC is built for long, sustained GH elevation from infrequent dosing. Tesamorelin is fast-acting, dosed daily, and backed by a much deeper pool of clinical data on visceral fat and metabolic outcomes specifically.

Which raises GH and IGF-1 higher

This is where CJC-1295 DAC actually wins. In the Teichman et al. 2006 trial (Journal of Clinical Endocrinology and Metabolism), a single dose produced GH increases of 2 to 10 fold lasting 6 or more days, and IGF-1 elevations of 1.5 to 3 fold lasting 9 to 11 days. Its measured half-life was 5.8 to 8.1 days, meaning one injection kept the GH axis elevated for close to a week. Tesamorelin also raises GH and IGF-1, but its effect is far shorter, which is why it's dosed daily in clinical use instead of weekly.

Which has more human data behind it

Not close. Tesamorelin has gone through large randomized trials with hundreds of participants followed for 6 to 12 months, including its pivotal FDA trial. CJC-1295's strongest human research is a much smaller pharmacokinetic study that confirms it reliably raises GH and IGF-1, but there's no equivalent large trial data showing what that translates to for visceral fat, liver fat, or broader metabolic health.

Impact on metabolic health

Tesamorelin wins here too, and the data is specific. The pivotal trial randomized 412 patients with HIV-associated abdominal fat accumulation to tesamorelin or placebo for 26 weeks (NEJM, 2007). Visceral fat dropped 15.2% in the tesamorelin group versus a 5.0% increase on placebo, and triglycerides fell by 50 mg/dL versus a 9 mg/dL rise on placebo. That's the population tesamorelin's approval is actually based on, HIV-related lipodystrophy, though follow-up studies have shown similar visceral and liver fat reductions outside that specific population too. CJC-1295 could plausibly produce comparable GH-mediated effects on the same logic, it just hasn't been tested at anywhere near this scale to confirm it.

Pharmacological comparison

CJC-1295 DAC: extremely long acting, sustained GH and IGF-1 elevation from infrequent dosing, better suited if the goal is simply prolonged GH-axis stimulation. Tesamorelin: shorter acting, far more extensively studied in humans, with the strongest evidence specifically for visceral fat reduction and effects that are well characterized rather than inferred.

Bottom line

If the question is purely which compound keeps GH and IGF-1 elevated longer, CJC-1295 wins on paper. If the question is which one has demonstrated real-world outcomes in actual clinical trials, tesamorelin wins clearly, and it isn't close.

TL;DR

• Both compounds work through the GHRH receptor, but CJC-1295 DAC is built for long, infrequent GH stimulation while tesamorelin is short-acting and dosed daily.
• A 2006 trial (Teichman et al.) found a single CJC-1295 DAC dose raised GH 2 to 10 fold for 6+ days and IGF-1 1.5 to 3 fold for 9 to 11 days, with a half-life of 5.8 to 8.1 days.
• Tesamorelin has been tested in large randomized trials with hundreds of participants, while CJC-1295's strongest human data is a smaller study confirming it raises GH and IGF-1 without matching evidence on downstream outcomes.
• Tesamorelin's pivotal 412-patient trial found a 15.2% visceral fat reduction and a 50 mg/dL triglyceride drop over 26 weeks, in the HIV-lipodystrophy population its approval is based on.
• CJC-1295 could theoretically produce similar metabolic effects through the same GH-mediated mechanism, but that hasn't been demonstrated at scale.
• CJC-1295 wins on duration of GH elevation, tesamorelin wins clearly on real-world clinical evidence.

Check out the pinned Peptide Cheat Sheet for dosing info and more.

Not medical advice. Educational only.

There's a claim that keeps getting repeated as gospel in this space: BPC-157 has to go in right at the injury site or it does nothing, like it's incapable of repairing anything except the exact spot where the needle went in. Half true, half myth. Worth actually sorting out.

Here's the reality. BPC-157 works systemically. Once it enters circulation, it travels through the whole body and acts wherever there's damage. It doesn't stay parked at the injection site waiting for something to happen locally. That means it doesn't have to land at the exact target to produce an effect. A subcutaneous shot in your abdomen still reaches a torn rotator cuff or a cranky knee through the bloodstream.

Where the Site-Specific Idea Actually Has Merit

The kernel of truth here is local concentration. In the first 15 to 30 minutes after injection, before the peptide fully diffuses into systemic circulation, the tissue nearest the injection site sees a meaningfully higher concentration than the rest of the body. For something stubborn, a tendon that's been dragging on for months, placing the shot closer to that structure isn't pointless. It's a real, if modest, edge during that early diffusion window.

Animal research backs this up too. Studies on local BPC-157 administration in ligament injury models have shown measurable improvements across functional, biomechanical, and histological markers when the peptide was delivered near the damaged tissue specifically.

What This Actually Means in Practice

A dose injected away from the target isn't wasted. It still reaches the site of damage through normal circulation, same as any systemically absorbed compound would. Injecting closer to a stubborn local injury is a minor optimization, not a requirement. Nobody needs to stress about hitting the exact tendon or worry that a slightly-off injection just wasted the dose.

Where this distinction matters more practically: for anything inaccessible, a deep hip joint, an internal structure, anything you genuinely can't inject near, the abdomen works fine for systemic delivery. For post-surgical recovery where the actual site is bandaged or sutured, systemic delivery from the abdomen is the better call anyway, since injecting near a fresh surgical wound just adds unnecessary infection risk for a marginal concentration benefit you don't need.

One related mistake worth avoiding: splitting a single dose across multiple injury sites to try to cover more ground. That just delivers a subtherapeutic concentration everywhere instead of an effective one anywhere. If you're dealing with two separate injuries, alternating full doses across sites on different days works better than fragmenting one dose across both at once.

TL;DR

• BPC-157 works systemically once absorbed, reaching damaged tissue throughout the body regardless of where it's injected.
• Injecting near the target does create a real but temporary local concentration advantage during the first 15 to 30 minutes before full systemic diffusion.
• A dose placed away from the injury isn't wasted. It still gets there through circulation.
• Near-site placement is a minor optimization for stubborn local injuries, not a requirement for the compound to work.
• For inaccessible injuries or post-surgical sites, systemic abdominal injection is the more practical and often preferable choice.
• Splitting one dose across multiple injury sites delivers a subtherapeutic concentration at each and should generally be avoided.

Check out the pinned Peptide Cheat Sheet for more.

Not medical advice. Educational only.

Everyone talks about the number on the scale. Retatrutide changes a lot more than that, and most of it doesn't show up until you're already a few weeks in.

You may forget about food entirely

Retatrutide doesn't just make your stomach feel full. Its GLP-1 and GIP activity reaches brain circuits involved in appetite, cravings, and food reward. Foods that used to be hard to resist can suddenly feel uninteresting, and a lot of people describe a sharp drop in food noise, to the point of forgetting meals altogether. That makes dieting easier in one sense and harder in another. You still need enough protein, calories, and micronutrients even when your brain has stopped asking for them.

Your digestion changes, especially early on

GI effects are common during dose escalation: nausea, constipation, diarrhea, bloating, and feeling full almost immediately. GLP-1 signaling slows gastric emptying, particularly in the earlier stages of treatment, so meals that used to feel normal can suddenly feel oversized. Large, fatty meals tend to be the hardest to tolerate during this period.

Losing too much, too fast, isn't automatically good

Watching the scale move every week feels like progress, but retatrutide doesn't guarantee that everything lost is fat. A body composition substudy of retatrutide in people with type 2 diabetes found the ratio of lean mass lost to total weight lost was comparable to other obesity treatments, not worse, but also not zero. Rapid weight loss can still take lean tissue with it if protein intake and resistance training aren't part of the plan. The actual goal is losing fat while keeping the muscle underneath it.

You may still feel hungry, and that doesn't mean it stopped working

Appetite suppression isn't uniform. It varies between people and can shift throughout treatment. Part of that is biological: significant weight loss activates systems in the body built to defend your previous bodyweight, which can bring some hunger back even while the compound is still active. Feeling hungrier later usually means it's time to reassess dose, timing, or take a planned break, not that the compound has quietly stopped doing anything.

Some of the most important changes never show up in the mirror

The scale and the mirror get all the attention, but the internal numbers move a lot too. In Phase 3 TRIUMPH data, retatrutide at the 12 mg dose reduced liver fat by roughly 82% at 24 weeks, with the majority of participants who had fatty liver at baseline no longer meeting that threshold afterward. Separate trial data has shown meaningful drops in non-HDL cholesterol and triglycerides, along with blood pressure reductions in the range of 10 to 14 mmHg, and measurable decreases in hs-CRP, a marker of systemic inflammation. Blood glucose and HbA1c improvements track closely with these changes too. Your waistline shrinking is the visible part. Your metabolic health moving is often the bigger part.

Bottom line

Retatrutide isn't just inject, lose appetite, lose weight. It changes how much you want to eat, what foods appeal to you, how meals physically feel, and how your body processes energy at a level you can't see on a scale. Knowing what's coming ahead of time makes the whole experience a lot easier to navigate.

Check out the pinned Peptide Cheat Sheet for more info.

Not medical advice. Educational only.

CJC-1295 has reached a kind of cult status in this space. It's often the entry-level recommendation people hear about first, treated as a near-universal answer for recovery, fat loss, and sleep. That popularity glosses over a more complicated reality underneath.

TL;DR

• CJC-1295 with DAC extends half-life to 5 to 9 days through an albumin-binding maleimide group, versus roughly 30 minutes for the No DAC version (Mod GRF 1-29).
• Continuous GH elevation from DAC keeps the body biased toward growth signaling (mTOR) rather than cellular repair (autophagy), which is the opposite direction from what GLP-1 compounds like tirzepatide or retatrutide push toward.
• A 2006 Phase 2 trial was halted after a participant died of a heart attack roughly two hours after their 11th weekly injection. The death was attributed to pre-existing coronary artery disease, though that attribution was never independently confirmed since the trial's data was never formally published.
• In December 2024, an FDA advisory panel voted against adding CJC-1295 to the legal compounding list, citing nonclinical toxicity, an unresolved cardiac signal, and immunogenicity risk.
• Injecting in a fed state blunts the pituitary's ability to release GH because elevated insulin interferes with somatotroph signaling. Fasting 60 to 120 minutes around your dose matters.
• Pairing CJC-1295 with a ghrelin receptor agonist like ipamorelin produces a genuinely synergistic GH response through two separate receptor pathways, not just an additive one.

DAC vs No DAC: The Half-Life Tradeoff

The most misunderstood decision in this space is DAC versus No DAC.

CJC-1295 No DAC, commonly called Mod GRF 1-29, has roughly a 30-minute half-life and produces a single, sharp GH pulse that mimics the body's natural pattern.

CJC-1295 with DAC extends that half-life to somewhere around 5 to 9 days by adding a modified lysine carrying a maleimide group at the 30th position. That group binds to albumin in the blood, keeping the peptide circulating for an extended period rather than clearing quickly.

Sustained elevation sounds efficient on paper, but there's a real tradeoff. Continuously raising the GH baseline keeps the body biased toward growth signaling through mTOR rather than the cellular repair and cleanup that happens through autophagy. That's the opposite direction from what GLP-1 compounds like tirzepatide or retatrutide are doing metabolically, which lean toward autophagy and cellular maintenance.

Think of GH like a lighthouse. The dark gaps between sweeps of light are part of the design, giving receptors a chance to reset. Constant light isn't a stronger signal. It's just noise the system stops responding to properly.

The Trial Death and Where the Regulatory Picture Stands Now

Peptide veterans will remember the 2006 Phase 2 trial in HIV-associated lipodystrophy that got halted after a participant died. The death happened about two hours after the participant's 11th weekly injection, and the cause was attributed to pre-existing, asymptomatic coronary artery disease with plaque rupture. That attribution was never independently confirmed in the published literature, largely because no efficacy or safety data from that trial program was ever formally published. The sponsor never resumed development, and no other company has taken CJC-1295 with DAC back into clinical trials since.

More recently, in December 2024, FDA's Pharmacy Compounding Advisory Committee voted against adding CJC-1295 to the 503A bulk compounding list, specifically citing nonclinical toxicity findings, an unresolved cardiac signal, and immunogenicity risk. That vote reflects ongoing regulatory caution around the compound's cardiovascular profile, not just historical baggage.

The Side Effect Picture

CJC-1295 is a potent GHRH analog, and it's known to trigger histamine and mast cell activation responses in a meaningful number of users. Injection site reactions, welts and redness, headaches, and in some cases transient hives are commonly reported. Specific percentage figures circulate widely across peptide vendor and community sources, sometimes citing numbers as high as 70% for injection site reactions, but since the original 2006 trial data was never formally published, these specific figures should be treated as commonly repeated community estimates rather than confirmed peer-reviewed statistics.

Because rare but serious allergic reactions have been reported with this compound, starting at a conservative dose, sometimes described as a tier one test dose around 100mcg, functions as a practical screen for allergic sensitivity before escalating further.

Why Fasted Dosing Actually Matters

A common complaint is being a non-responder to CJC-1295. Usually the issue isn't the peptide. It's timing.

There's a real physiological conflict between insulin and pituitary GH release. When insulin is elevated, it blunts the somatotroph cells' ability to release stored GH. Injecting in a fed state means signaling a pituitary that's functionally less responsive at that moment.

The practical guidance: inject at minimum 60 minutes before or after eating, ideally 90 to 120 minutes out. Bedtime dosing tends to work well because it naturally aligns with a fasted state and the body's largest natural GH pulse, which occurs shortly after sleep onset.

Why Ipamorelin Isn't Optional

CJC-1295 hits the GHRH receptor. Ipamorelin hits an entirely separate ghrelin receptor pathway. These aren't redundant compounds stacked for no reason, they converge on the same pituitary cells through different mechanisms to produce a GH response that's genuinely greater than either one alone.

Ipamorelin specifically earned its reputation as the cleanest compound in its class after a 1998 characterization study showed it doesn't meaningfully raise cortisol, prolactin, or reproductive hormones, even at doses roughly 200 times the effective dose for GH release. That selectivity is why it's the preferred pairing over older ghrelin receptor agonists.

Where the Molecule Actually Came From

The history here traces back to 1982, when researchers Roger Guillemin and Jean Rivier isolated GHRH from a pancreatic tumor, turning a theoretical hypothalamic hormone into an actual defined molecule. Natural GHRH is fragile though, broken down by the DPP-IV enzyme within about 10 minutes of release.

To solve that, researchers engineered four specific amino acid substitutions to create what's now called Mod GRF 1-29. D-alanine at position 2 is the most critical change, blocking DPP-IV from recognizing its usual cut site entirely. Glutamine at position 8 improves stability both in solution and in the body. Alanine at position 15 adjusts the molecule's shape for tighter receptor binding. Leucine at position 27 replaces methionine specifically to prevent oxidative degradation from air exposure. Together these modifications are what separate CJC-1295 from older, less stable compounds like sermorelin, which lacks this stabilization and clears the body almost immediately.

Who This Actually Makes Sense For

CJC-1295 tends to matter most for people between roughly 35 and 55 who are noticing a real decline in recovery capacity. After age 50 or so, the pituitary naturally fires less forcefully. CJC-1295 functions as a volume knob on that existing signal rather than replacing it with exogenous hormone.

None of this works if the foundation underneath it is broken. Low testosterone, ignored thyroid dysfunction, inadequate protein intake, any of these will undermine the peptide regardless of protocol. For people with those basics handled, a cycle length of roughly 12 to 16 weeks on followed by 4 to 6 weeks off is the commonly discussed approach for avoiding receptor desensitization.

Check out the pinned Peptide Cheat Sheet for more.

Not medical advice. Educational only.

So you've hit your target weight on a GLP-1 medication (like Reta, Tirz, Sema) and you're wondering what comes next. Can you just stop taking it, or do you need to gradually reduce your dose? This is actually one of the most important questions to consider as you approach your goals, and the answer isn't as straightforward as you might think.

Maintenance Dosing vs. Stopping Completely

Once you reach your goal weight, you basically have two paths forward. The first option is tapering down to a maintenance dose, essentially finding the lowest amount that helps you maintain your results without continuing to lose weight. (This is actually my preference)

The second option is stopping the medication entirely. Whichever route you choose, the lifestyle changes you've built while on the medication (better eating habits, regular exercise, etc.) become absolutely critical for keeping the weight off long-term.

Why Tapering Matters

GLP-1s have a half-life of about 6-7 days, meaning it takes nearly a week for half the dose to clear your system. They also take 4-5 weeks to reach steady levels in your bloodstream.

Because they strongly suppress appetite and slow digestion, stopping abruptly can cause a significant rebound effect and suddenly your hunger comes roaring back to where might find yourself struggling with the same issues that led you to start the medication in the first place.

The smarter approach is gradually lowering your dose over time, which allows your body to adjust naturally and gives you the best shot at maintaining your results alongside those healthy habits you've developed.

Checkout the pinned Peptide Cheat Sheet for more info.

Not medical advice. Educational only.

Everyone repeats it like scripture: never shake a peptide vial, only swirl, or you'll destroy the peptide. Said with total confidence, like it's settled science. But Janoshik, one of the testing labs this whole community actually trusts for purity data, has openly stated shaking doesn't degrade peptides. So which version is right?

The Actual Answer

The "shaking denatures peptides" rule got carried over from large, fragile proteins like antibodies, where mechanical shear stress at the air-liquid interface genuinely can cause aggregation and structural damage during shaking. That's real, documented pharmaceutical science, just for a completely different category of molecule.

Most research peptides are short and structurally simple compared to something like an antibody, and they don't degrade from the physical act of shaking the way larger, more complex proteins do. Janoshik has stated directly, in a documented interview, that they've tested this specifically and shaking didn't compromise potency. Room temperature degradation from normal handling tends to be minimal, in the low single digits, not the dramatic degradation the community myth implies. On the question of whether the peptide survives being shaken, the lab wins that argument.

Where the Swirl Advice Still Holds Up

The one place the traditional advice still has a real point is foaming. Shaking whips air into the solution and creates foam and bubbles. That doesn't damage the peptide itself, but it makes drawing an accurate dose genuinely harder, and an inconsistent draw can throw off your actual measured amount more than the shaking ever would have.

So the real reason to swirl instead of shake isn't that shaking kills the peptide. It's that foam makes dosing sloppy and inconsistent, which is a practical problem worth avoiding regardless of whether the underlying myth about degradation is true.

Where This Leaves the Myth

Shaking won't destroy your peptide. That part of the rule is false, and the lab data backs that up directly. Swirling is still the cleaner practice, not because it protects potency, but because it keeps the solution bubble-free and easier to draw accurately. The myth is half right. The "it degrades" part doesn't hold up. The "swirl for a clean draw" habit is still solid practice, just for a completely different reason than most people think.

Checkout the pinned Peptide Cheat Sheet for more.

Retatrutide and Cagrilintide, two compounds already covered separately on this sub, are increasingly showing up together in a single combined formulation. The idea is hitting fat loss from two different angles simultaneously, and on paper it's about the most aggressive combination currently circulating. It also stacks the downsides, and running them together comes with a real practical catch most people miss.

How the Two Compounds Actually Work

Retatrutide and Cagrilintide operate through completely different mechanisms. Retatrutide is the triple agonist, hitting GLP-1, GIP, and glucagon receptors. The GLP-1 and GIP components drive appetite suppression, while the glucagon arm specifically pushes up energy expenditure, something the GLP-1 monotherapies don't do.

Cagrilintide works an entirely separate pathway. It's a long-acting amylin analog acting on amylin receptors in the hindbrain, slowing gastric emptying and driving satiety through a mechanism that doesn't overlap with incretin signaling at all.

So combining them runs four mechanisms simultaneously: GLP-1, GIP, glucagon, and amylin. Retatrutide handles the metabolic and appetite side. Cagrilintide layers a structurally distinct satiety mechanism on top of it.

Where the Idea Comes From

The rationale for this combination comes from CagriSema, Novo Nordisk's cagrilintide plus semaglutide pairing. In the Phase 3 REDEFINE 1 trial, CagriSema produced 20.4% average weight loss at 68 weeks (rising to 22.7% among fully adherent participants), meaningfully outperforming semaglutide alone (14.9%) and cagrilintide alone (11.5%). Stacking amylin-driven satiety on top of an incretin pathway produced more appetite control than either mechanism running solo.

Pairing reta with cagri runs that exact playbook but swaps in the strongest incretin currently available in place of semaglutide. It's the most aggressive version of a strategy that's already been validated in a completely different compound pairing.

The First Real Catch: No Combination Data Exists

Retatrutide on its own is still in Phase 3 trials with no approval anywhere in the world. Retatrutide plus cagrilintide combined has zero human trial data behind it, none. You're stacking two individually investigational compounds and extrapolating combined efficacy and safety from what each does alone. Neither the combined effectiveness nor the combined risk profile has actually been studied in a controlled setting. Go in with that clearly understood.

The Second Catch: The Fixed Ratio Problem

When these two compounds are sold together in a single pre-mixed vial, they typically ship at a fixed ratio, commonly around 10:1, 5mg of retatrutide to 0.5mg of cagrilintide. That means the two compounds can't be titrated independently. They move up and down together as a single unit.

That's a real limitation. Retatrutide specifically needs careful, gradual titration on its own, and if a side effect appears while running a fixed combination, there's no way to determine which compound is responsible or to pull back just one of them.

The ratio also means the amylin dose lands light relative to standalone cagrilintide protocols. At 2mg of retatrutide, you're only getting 0.2mg of cagrilintide, below where cagrilintide monotherapy protocols typically even begin. In practice, a fixed 10:1 combination functions as a retatrutide protocol with a modest amylin assist layered on top, not a full therapeutic dose of both compounds.

Dosing Structure

Based on a common 10:1 fixed ratio formulation:

Weeks	Retatrutide content	Cagrilintide (at 1/10)
1 to 4	1mg/week	0.1mg
5 to 8	2mg/week	0.2mg
9 to 12	4mg/week	0.4mg
Maintenance	6 to 8mg/week	0.6 to 0.8mg

Dosing runs off the retatrutide content, once weekly. Reconstitute with 1mL of BAC water to get 5mg/mL of retatrutide, with cagrilintide carried along proportionally. That works out to 1mg retatrutide = 0.2mL, 2mg = 0.4mL, 4mg = 0.8mL. Subcutaneous injection, once per week.

Hold each dosing step for a minimum of 4 weeks before increasing, the same rule that applies to retatrutide alone, since it has roughly a six-day half-life and takes several weeks for a given dose to fully express its effect.

Side Effects to Actually Expect

Because both compounds hit the GI tract, nausea and gastrointestinal side effects stack rather than staying at either compound's baseline individually, which makes slow titration more important here, not less. Retatrutide's glucagon-driven resting heart rate increase still applies on top of that, worth tracking weekly as you escalate, especially if you're already lean. Appetite suppression coming from two separate directions simultaneously can get aggressive enough to cause real undereating and muscle loss, making adequate protein intake and resistance training non-negotiable rather than optional on this protocol. Expect nausea, strong appetite suppression, some fatigue, and a likely resting heart rate bump.

Who This Actually Makes Sense For

If you've never run retatrutide by itself, do that first. Understanding your individual response to the triple agonist alone matters before adding a second compound you can't separate from it in a fixed-ratio product. This is a combination for experienced researchers who already know their retatrutide response, not a reasonable starting point. It remains entirely investigational with no regulatory approval anywhere, so product purity depends entirely on sourcing.

Checkout the pinned Peptide Cheat Sheet for dosing info and more.

Not medical advice. Educational only.

If you've spent any time in peptide communities, you've seen the same questions on repeat. How do I reconstitute this? How many units do I draw? What am I actually looking at on this COA? Is 97% purity good enough? The answers exist - they're just buried across thousands of threads, comment sections, and pinned posts that are three years old.

We built peptide-guide.co to fix that. One spot.

What's actually there

The Basics 101 page covers the full workflow from powder to injection: hygiene and sanitization, reconstitution, concentration math, dosing calculations, SubQ vs IM administration, combining peptides in one syringe, storage by vial type, and travel notes. It's written for someone who's never held an insulin syringe, but it doesn't talk down to people who have.

The COA guide is the part we're most proud of. It walks through an actual ISO/IEC 17025 accredited COA - not a hypothetical, a real one - field by field. Most guides tell you "look for 95%+ purity." This one explains the difference between purity screening and sterility screening, what endotoxin testing is and why it matters, what the batch/lot number match actually means, and how to verify the report independently using the lab's QR code. If a vendor's COA doesn't resolve on the lab's own domain, that's a problem. Most people don't know to check that.

The reconstitution calculator handles the math that trips people up most often. Vial size, BAC volume, target dose in mcg - put in what you have, get back the units to draw. No conversion errors, no unit confusion.

A guides library is live and we're publishing compound-specific content consistently. It's early, but the framework is there.

https://preview.redd.it/7lxxhbgpmenh1.png?width=1342&format=png&auto=webp&s=674cccf8b93819eac82ff68db384ea3995281dfe

peptide-guide.co

Bioregulators don't work like most compounds in this space, and using them the wrong way, the way people use BPC-157 or CJC-1295, mostly just wastes the product. Here's how they're actually structured and used, and where the evidence genuinely stands for each one.

Why These Aren't Dosed Like Normal Peptides

Most peptides in this space work through receptor stimulation. You dose, the receptor activates, the effect happens, and it fades as the compound clears. Bioregulators are proposed to work differently, through direct interaction with chromatin and gene regulatory regions inside the cell, essentially nudging gene expression back toward a more youthful pattern rather than triggering an acute signal.

That mechanistic difference is why these are traditionally run in short, defined courses rather than continuous daily dosing. The Russian clinical model has generally used courses lasting roughly 10 to 20 days, followed by an extended break, sometimes repeated once or twice a year rather than run continuously. The logic is that the effect is a gene expression shift, not a sustained receptor occupation, so continuous exposure isn't the goal the way it might be with a GH secretagogue.

Matching the Compound to the Tissue

Cartalax targets cartilage and connective tissue, relevant for joint wear, aging athletes, and post-surgical joint recovery.

Cardiogen targets cardiac tissue, studied for myocardial cell function and age-related cardiac support.

Vesugen (Lys-Glu-Asp) targets vascular tissue specifically, endothelial and smooth muscle cells, with proposed effects on vascular tone and endothelial barrier function through gene expression changes in the vessel wall.

Vilon (Lys-Glu) is an immune-targeted bioregulator, one of the simpler two-amino-acid compounds in the family, studied for general immune function support.

Thymalin, a thymus-derived extract rather than a short synthetic peptide, has the deepest human clinical track record of the entire category. Long-term Russian geriatric studies following patients over six years found meaningful reductions in all-cause mortality with regular Thymalin use, and even larger reductions when combined with a pineal-derived compound. This is genuinely the strongest data point in the whole bioregulator conversation.

Prostamax (Lys-Glu-Asp-Pro) is the tetrapeptide associated with prostate tissue. Worth being precise here: the human clinical data people often cite for prostate benefits in this space actually belongs to Prostatilen, a related prostate tissue extract with real published human data in prostatitis and benign prostatic conditions. Prostamax the synthetic short peptide has much thinner evidence behind it, mostly chromatin-level and rodent tissue findings rather than direct human outcome data. Don't let the naming similarity between the two products borrow credibility that belongs to the extract, not the synthetic peptide.

Stacking With Signaling Peptides

The general framework worth understanding: bioregulators are proposed to work on a slower, structural timeline, supporting the cellular and genetic environment of a specific tissue, while signaling peptides like BPC-157, TB-500, or KPV work faster and more acutely, driving the actual repair signal.

The logic for combining them is straightforward. A signaling peptide can drive a repair response, but if the underlying tissue environment is compromised, that signal has less to work with. Running a tissue-specific bioregulator alongside the signaling peptide is meant to address both layers at once, foundation and signal, rather than relying on the acute peptide to do all the work.

Being Honest About Where the Evidence Actually Sits

This entire category, outside of Thymalin's mortality data and a handful of other Russian clinical studies, sits closer to preclinical and observational than it does to the kind of evidence base people expect from GLP-1s or other well-studied peptides. Decades of published research exist, but almost none of it has been independently replicated in Western trials, and much of what circulates in vendor marketing conflates a synthetic peptide's evidence with an extract's evidence, or vice versa, when the two are not the same product.

That doesn't mean the category isn't worth understanding. It means going in with accurate expectations about what's actually been shown versus what's simply been proposed.

TL;DR

• Bioregulators aren't dosed like conventional peptides. They're run in short, defined courses rather than continuous daily use, because the mechanism is gene expression signaling, not receptor stimulation that needs to be maintained.
• Each one targets a specific tissue: Cartalax for cartilage, Cardiogen for cardiac tissue, Vesugen for vascular and endothelial tissue, Vilon for immune tissue, Thymalin for thymic and broader immune function, and Prostamax for prostate tissue.
• Thymalin has the strongest human evidence in the entire family, including long-term Russian geriatric studies showing significant reductions in all-cause mortality.
• Prostamax the synthetic peptide has much thinner evidence than commonly claimed. The stronger prostate clinical data actually belongs to Prostatilen, a related tissue extract, not the synthetic peptide itself.
• They're commonly paired with signaling peptides like BPC-157 or KPV, with the bioregulator supporting the underlying tissue environment while the signaling peptide drives the acute repair response.
• The evidence base overall is still mostly Russian and preclinical to observational in quality, genuinely under-researched by Western standards, not a settled science.

Not medical advice. Educational only.

MOTS-C and SS-31 keep showing up together in the same conversations, and it's not random. They both work on mitochondria, but they're not doing the same job, which is exactly why the pairing makes sense.

The role of MOTS-C

MOTS-C is a mitochondrial-derived peptide that acts as a metabolic regulator. It activates AMPK, the cell's primary energy-sensing pathway, improves insulin sensitivity and glucose uptake, and increases fat oxidation and metabolic flexibility. A 2021 USC study found it reduced myostatin, a natural limiter on muscle growth, by 40% in mice on a high-fat diet. In practical terms, MOTS-C makes cells better at adapting to energy demand, so training feels more productive and fatigue builds more slowly. Worth flagging plainly: this is mouse data. MOTS-C hasn't been tested in a human trial yet.

The role of SS-31

SS-31, also called elamipretide, works at the structural level. It binds cardiolipin in the inner mitochondrial membrane, stabilizes electron transport chain function, and reduces reactive oxygen species production. Here's a correction worth making: SS-31 doesn't just protect mitochondria from damage. It actively improves ATP output per unit of fuel, meaning it upgrades how efficiently mitochondria run, not just how well they survive stress. That's a meaningfully different claim than pure protection, and it's the more accurate one.

Why they stack so well

MOTS-C increases metabolic demand and adaptability. SS-31 keeps the machinery meeting that demand from breaking down under it. Push metabolism harder without SS-31 and oxidative stress can build up over time. Have protected mitochondria without MOTS-C pushing them, and they may sit below their adaptive potential instead of actually getting better. Together, the idea is more energy capacity, less energy waste, and less oxidative damage while you're pushing training or a deficit harder.

Effects on body composition

The combination is pitched as easier fat loss through better fuel partitioning, better muscle retention in a deficit, more training volume tolerance, and faster recovery between sessions. MOTS-C improves how muscle uses nutrients and responds to training. SS-31 is meant to let mitochondria sustain that workload without excessive damage or fatigue. Worth being clear that this specific combination hasn't been tested together in any trial, mouse or human. The logic connects two real mechanisms, it isn't a measured outcome of the stack itself.

Energy, recovery, and anti-aging

Mitochondrial dysfunction is genuinely tied to chronic fatigue, poor recovery, insulin resistance, and accelerated aging in the broader research literature. MOTS-C addresses the signaling and adaptation side of that picture. SS-31 addresses the structural and oxidative side. That combination is why the stack gets attention from people focused on healthspan and aging, not just body composition.

Bottom line

MOTS-C and SS-31 stack well because they respect two different layers of mitochondrial biology instead of overlapping. MOTS-C improves how cells adapt and respond. SS-31 improves how efficiently the energy-producing machinery itself runs. The mechanism case is genuinely strong. Just keep in mind MOTS-C's data is animal-only for now, and nobody has tested this exact pairing together.

TL;DR

• MOTS-C activates AMPK and improves insulin sensitivity, fat oxidation, and reduces myostatin signaling, based entirely on mouse studies so far.
• SS-31 actively improves ATP output and electron transport chain efficiency, not just protection from damage, which is a more accurate description than "protective only."
• The stacking logic works because MOTS-C increases metabolic demand while SS-31 keeps mitochondria from breaking down under that demand.
• Body composition claims like easier fat loss and better recovery follow from the individual mechanisms but haven't been measured as an outcome of this specific combination.
• Mitochondrial dysfunction is broadly linked to fatigue, insulin resistance, and aging, which is why this stack gets attention beyond just body composition.
• MOTS-C's evidence is animal-only right now, and this exact pairing hasn't been tested together in any trial.

Not medical advice. Educational only.

Most people running tesamorelin blame the compound when results stall. Usually it's not the compound. Here are the four things that actually decide whether a cycle delivers or underperforms.

1. Protect the GH pulse with sleep

Tesamorelin works by amplifying your natural GH pulse, and that pulse peaks during deep, slow-wave sleep. Poor sleep caps the pulse before tesamorelin has much to amplify, so weak sleep quietly undercuts the whole protocol regardless of dose. A consistent sleep schedule, a dark and cool room, no late-night screens, and winding down before bed all matter more here than people expect.

2. Match your deficit to fat loss, not muscle loss

Tesamorelin mobilizes fat. It doesn't override bad math. Run calories too high and fat loss stalls even with a strong GH pulse. Run them too low and you start losing muscle along with fat. A moderate deficit, somewhere around 500 calories, with high protein and enough carbs to support training, is the range that actually lets tesamorelin do its job on visceral fat specifically.

3. Time it around insulin, not just around meals

This one's mechanism, not preference. Insulin and GH-driven lipolysis work against each other. When insulin is elevated, especially from carbs, the lipolytic effect of a GH pulse gets blunted. That's real, well-established endocrinology, not a community myth. What the community has converged on, pinning on an empty stomach and avoiding food for a few hours after, isn't something written into tesamorelin's FDA label. It's a practical protocol built on top of a real mechanism, and it holds up.

4. Stack with a specific reason, not just to stack

Tesamorelin works through the GH pathway, so pairing it with compounds hitting different pathways can compound results, if you're honest about what each one actually has evidence behind. Retatrutide as an appetite suppressant makes a deficit easier to hold, that's well supported. Testosterone support helps preserve muscle and performance during a deficit, also well supported. MOTS-C gets pitched as a fat mobilizer constantly, but essentially all of that data comes from mouse studies, not humans. It's a legitimate mechanism worth knowing about, just not proven at the human level the way the other two are.

Bottom line

Dose matters less than people think. Get these four right and you look leaner every week. Get them wrong and you cap what the compound can do.

TL;DR

• Tesamorelin amplifies your natural GH pulse, and that pulse peaks during deep sleep, so poor sleep quietly limits the compound regardless of dose.
• A moderate deficit around 500 calories with high protein and adequate carbs lets tesamorelin target visceral fat without triggering muscle loss.
• Elevated insulin blunts GH-driven lipolysis, which is why pinning fasted and avoiding food for a few hours after is standard community practice, though it isn't part of the FDA label.
• Retatrutide and testosterone support both have solid evidence behind stacking them with tesamorelin, for appetite control and muscle preservation respectively.
• MOTS-C gets pitched constantly as a stacking option for fat mobilization, but that data is almost entirely from mouse studies, not humans.
• Getting these four levers right matters more than the dose itself for how much visceral fat actually comes off.

Not medical advice. Educational only.